Literature DB >> 17997704

Trigeminal neuralgia: for one nerve a multitude of treatments.

William P Cheshire1.   

Abstract

Trigeminal neuralgia (TN) is reputed to be one of the most painful conditions in human experience. Thus, many treatments, both medical and surgical, have been developed for this relapsing and remitting, paroxysmal stabbing or electrical, facial pain syndrome. The likely etiology in many cases is vascular compression of the trigeminal nerve root entry zone, leading to focal demyelination and aberrant neural discharges. MRI may disclose neurovascular contact, although not with sufficient sensitivity or specificity to substitute for careful clinical diagnosis. In treating TN, antiepileptic drugs are superior to traditional analgesics. Carbamazepine is the first choice drug. Additional drugs for which there is evidence of efficacy include oxcarbazepine, baclofen, gabapentin, lamotrigine and phenytoin. Many patients eventually experience tachyphylaxis or may not tolerate effective doses. Surgical options include: microvascular decompression; balloon compression; radiofrequency thermocoagulation or glycerol rhizotomies; and subcutaneous alcohol branch blockade. Stereotactic gamma knife radiosurgery is a further option. Motor cortex stimulation and transcranial magnetic stimulation, although having shown initial promise for trigeminal neuropathic pain, seem to be ineffective for classical TN. The choice of drug, whether or when to operate, and which procedure to choose should be individualized to the particular needs and conditions of the patient.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17997704     DOI: 10.1586/14737175.7.11.1565

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  17 in total

1.  Minocycline attenuates mechanical allodynia and expression of spinal NMDA receptor 1 subunit in rat neuropathic pain model.

Authors:  Shaofeng Pu; Yongming Xu; Dongping Du; Meirong Yang; Xin Zhang; Junzhen Wu; Wei Jiang
Journal:  J Physiol Biochem       Date:  2012-11-01       Impact factor: 4.158

2.  Duration of remission phase of 36 Korean patients with glossopharyngeal neuralgia.

Authors:  Myong-Soo Kang; Do-Wan Kim; Sung-Min Kim; Chan Kim; Young-Ki Kim
Journal:  Korean J Anesthesiol       Date:  2013-04-22

3.  Motor cortex stimulation for facial chronic neuropathic pain: A review of the literature.

Authors:  Guillermo A Monsalve
Journal:  Surg Neurol Int       Date:  2012-10-31

4.  Treatment of trigeminal neuralgia: role of radiofrequency ablation.

Authors:  Dessy R Emril; Kok-Yuen Ho
Journal:  J Pain Res       Date:  2010-12-12       Impact factor: 3.133

5.  Effectiveness of the association between carbamazepine and peripheral analgesic block with ropivacaine for the treatment of trigeminal neuralgia.

Authors:  Laurinda Lemos; Ramalho Fontes; Sara Flores; Pedro Oliveira; Armando Almeida
Journal:  J Pain Res       Date:  2010-10-25       Impact factor: 3.133

6.  Pharmacological versus microvascular decompression approaches for the treatment of trigeminal neuralgia: clinical outcomes and direct costs.

Authors:  Laurinda Lemos; Carlos Alegria; Joana Oliveira; Ana Machado; Pedro Oliveira; Armando Almeida
Journal:  J Pain Res       Date:  2011-08-24       Impact factor: 3.133

Review 7.  The Neuralgias.

Authors:  Danielle Wilhour; Stephanie J Nahas
Journal:  Curr Neurol Neurosci Rep       Date:  2018-08-16       Impact factor: 6.030

8.  Conditional gene deletion reveals functional redundancy of GABAB receptors in peripheral nociceptors in vivo.

Authors:  Vijayan Gangadharan; Nitin Agarwal; Stefan Brugger; Imgard Tegeder; Bernhard Bettler; Rohini Kuner; Martina Kurejova
Journal:  Mol Pain       Date:  2009-11-19       Impact factor: 3.395

9.  Trigeminal injury causes kappa opioid-dependent allodynic, glial and immune cell responses in mice.

Authors:  Megumi Aita; Margaret R Byers; Charles Chavkin; Mei Xu
Journal:  Mol Pain       Date:  2010-01-29       Impact factor: 3.395

Review 10.  Botulinum Toxin Type a as a Therapeutic Agent against Headache and Related Disorders.

Authors:  Siro Luvisetto; Parisa Gazerani; Carlo Cianchetti; Flaminia Pavone
Journal:  Toxins (Basel)       Date:  2015-09-23       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.